Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

JBIO vs EDIT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

JBIO Captures Overall Composite Edge (32.6 SELL vs 48.4 HOLD), While EDIT Leads 4–2 on Growth & Valuation Pillars

JBIO Overall Winner 6-Pillar Tally: JBIO 2 – 4 EDIT Matrix Metrics: JBIO 6 – 2 EDIT

As of Nov 16, 2026, Jade Biosciences, Inc. (JBIO) captures the overall head-to-head institutional edge over Editas Medicine, Inc. (EDIT) on higher Unified Composite conviction (32.6/100 SELL vs. 48.4/100 HOLD) after splitting the core matrix 6–2 (led by Profitability & Quality, Options & Positioning), while EDIT wins 4–2 across the 6-pillar growth and valuation breakdown. JBIO trades at $15.34 (N/M Forward P/E, 0.0% operating margin) versus EDIT at $1.91 (N/M Forward P/E, -167.0% operating margin).

  • Composite vs. Pillar Nuance: While EDIT currently prints a higher short-term Unified Composite Score (48.4/100 HOLD vs. JBIO 32.6/100 SELL), JBIO captures the overall institutional head-to-head verdict (6–2 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -167.0% operating margin) and revenue trajectory (+0.0% vs. +37.4% YoY).
  • Technical & Structure Timing Caution: JBIO is currently in a Breakdown options structure phase (RSI 51.0); meanwhile EDIT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About JBIO vs EDIT
JBIO NASDAQ Head-to-Head Winner
Jade Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$15.34
-4.96% 1D
Market Cap $1.0B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.35β · 60% Vol
Unified Composite Score
32.6 / 100 SELL
Tech 20.0 Fund 44.0 Flow 73.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 51
RSI-14: 51.0 · SMA20: $15.01 · SMA50: $15.23
EDIT NASDAQ
Editas Medicine, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.91
-12.21% 1D
Market Cap $336.5M
TTM Revenue $50M
Forward P/E N/M
Beta / 30D Vol 2.32β · 102% Vol
Unified Composite Score
48.4 / 100 HOLD
Tech 33.0 Fund 55.0 Flow 69.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.3%), weak momentum, RSI 33
RSI-14: 33.4 · SMA20: $2.52 · SMA50: $2.61

6-Pillar Scorecard Institutional Category Breakdown (JBIO 2 – 4 EDIT)

Columns: Metric · JBIO · EDIT
1. Valuation Multiples EDIT
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 5.2x
2. Growth & Scale EDIT
Revenue Growth (YoY) +0.0% +37.4%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $50M
Market Cap $1.0B $336.5M
3. Profitability & Quality JBIO
Gross Margin N/A -73.3%
Operating Margin 0.0% -167.0%
Net Profit Margin 0.0% -144.9%
Return on Equity (ROE) -89.2% -147.4%
4. Balance Sheet & Cash Flow EDIT
Cash Generation (TTM) -$124M -$110M
Cash Flow Margin N/A N/A
Net Cash / Leverage $107M Net Cash $79M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning JBIO
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 73.0% (6th %ile) 95.8% (38th %ile)
Put/Call OI Skew N/A 0.29x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat EDIT
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Concentrated Oligopoly Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: JBIO (6) vs EDIT (2)
Institutional Metric JBIO EDIT Criterion Row Edge
Market Capitalization
Scale
$1.0B $336.5M Larger Scale JBIO
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +37.4% Higher Growth EDIT
Operating Margin (TTM)
Profitability
0.0% -167.0% Higher Margin JBIO
Net Profit Margin
Profitability
0.0% -144.9% Higher Margin JBIO
Return on Equity (ROE)
Capital Efficiency
-89.2% -147.4% Higher ROE JBIO
52-Week Range Position
Momentum
32% ($10–$28) 11% ($2–$4) Stronger Trend JBIO
Beta / 30D Volatility
Risk Regime
1.35β · 60% Vol 2.32β · 102% Vol Lower Realized Risk JBIO
Unified Institutional Score
Composite Signal
32.6 / 100 (SELL) 48.4 / 100 (HOLD) Higher Composite EDIT
Trailing 12M Revenue (USD)
Operating Scale
N/A $50M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A -73.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 5.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$124M ($107M Net Cash) -$110M ($79M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon JBIO +32.82 pp
JBIO: +13.88% · EDIT: -18.94%
3M Horizon EDIT +1.01 pp
JBIO: -34.86% · EDIT: -33.85%
6M Horizon EDIT +5.6 pp
JBIO: -30.3% · EDIT: -24.7%
1Y Horizon JBIO +83.47 pp
JBIO: +58.47% · EDIT: -25.0%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on JBIO vs EDIT. Trailing 12-month operating profitability (JBIO 0.0% vs EDIT -167.0%) and valuation multiples (JBIO N/M vs EDIT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

JBIO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-89.2% · N/M
EDIT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$50M
Gross Margin-73.3%
Op. Margin-167.0%
ROE / Fwd P/E-147.4% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
JBIO BREAKDOWN
141d in phase · OBV ACCUMULATION
Current IV 73.0%
IV Percentile 6th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact JBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EDIT BREAKDOWN
146d in phase · OBV NEUTRAL
Current IV 95.8%
IV Percentile 38th %ile
Put/Call OI Skew 0.29x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact EDIT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
JBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.0B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
EDIT Moat Profile Concentrated Oligopoly Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $336.5M market capitalization and -167.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published · CRISPR / Gene Editing

Investor FAQ JBIO vs EDIT Key Questions & Quantitative Answers

As of Nov 16, 2026, Jade Biosciences, Inc. (JBIO) captures the overall head-to-head institutional edge over Editas Medicine, Inc. (EDIT) on higher Unified Composite conviction (32.6/100 SELL vs. 48.4/100 HOLD) after splitting the core matrix 6–2 (led by Profitability & Quality, Options & Positioning), while EDIT wins 4–2 across the 6-pillar growth and valuation breakdown. JBIO trades at $15.34 (N/M Forward P/E, 0.0% operating margin) versus EDIT at $1.91 (N/M Forward P/E, -167.0% operating margin). Composite vs. Pillar Nuance: While EDIT currently prints a higher short-term Unified Composite Score (48.4/100 HOLD vs. JBIO 32.6/100 SELL), JBIO captures the overall institutional head-to-head verdict (6–2 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -167.0% operating margin) and revenue trajectory (+0.0% vs. +37.4% YoY). Technical & Structure Timing Caution: JBIO is currently in a Breakdown options structure phase (RSI 51.0); meanwhile EDIT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

EDIT leads the Growth & Scale pillar: JBIO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with EDIT at +37.4% YoY revenue growth and +0.0% YoY earnings growth on $50M TTM revenue (-73.3% gross margin, -167.0% operating margin). On trailing 12-month operating scale, JBIO generates N/A in USD-normalized revenue versus $50M for EDIT. In operating R&D and SG&A reinvestment, JBIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EDIT.

EDIT screens cheaper on headline valuation multiples. JBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas EDIT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 5.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against JBIO (-89.2% ROE) versus EDIT (-147.4% ROE) capital efficiency.

In options market volatility and institutional positioning, JBIO carries 73.0% implied volatility (6th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.35β · 60% Vol realized risk). By comparison, EDIT carries 95.8% implied volatility (38th %ile, Balanced (25th–60th %ile)), a 0.29x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.32β · 102% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.